查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1970862

腕隧道症候群市场－全球产业规模、份额、趋势、机会、预测：按诊断、治疗、地区和竞争对手划分，2021-2031年

Carpal Tunnel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis, By Treatment, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球腕隧道症候群市场预计将从 2025 年的 9.8123 亿美元成长到 2031 年的 12.1671 亿美元，复合年增长率为 3.65%。

此市场领域涵盖用于诊断和治疗腕部正中神经压迫的手术器材、药品和医疗设备。推动这一增长的主要因素包括：数位化和久坐生活方式导致的重复性劳损日益普遍，以及全球人口老化加剧，老年人更容易患上肌肉骨骼疾病。此外，肥胖和糖尿病等合併症发病率的上升也持续增加需要临床介入的患者数量。英国健康与安全部门的数据显示，2024年英国职业伤害与残障福利计画将正式确认105例腕隧道症候群新病例，这进一步印证了该疾病的职业因素依然存在。

市场概览
预测期 2027-2031
市场规模：2025年 9.8123亿美元
市场规模：2031年 1,216,710,000 美元
复合年增长率：2026-2031年 3.65%
成长最快的细分市场 製药
最大的市场 北美洲

儘管存在这些有利的成长要素，但由于手术切除费用高成本以及术后併发症风险，市场仍面临许多障碍。发展中地区的经济限制，加上其他非侵入性治疗方法的出现，往往导致患者延后或避免接受更复杂的治疗。这些经济限制和保守的治疗方法选择有效地限制了市场的整体扩张。

市场驱动因素

微创手术技术，特别是超音波导引腕隧道鬆解术的日益普及，是推动市场成长的主要动力。与传统开放性手术相比，这些先进的手术切口更小，恢復时间更短，提高了患者的接受度，并促进了以诊所为基础、更经济高效的治疗模式的转变。这项技术进步既满足了门诊治疗的需求，也减轻了住院带来的经济负担。根据Sonex Health于2024年6月发布的ECRI积极评估报告，医生已开展了超过31,000例超音波引导腕管松解术，显示该技术在临床实践中得到了迅速应用。手术量的增加反映了市场正朝着以设备为中心、最大限度减少医疗资源消耗的解决方案转变。

同时，代谢性疾病及其相关併发症（例如类风湿性关节炎）的发生率不断上升，导致需要治疗的患者群体日益扩大。全身性发炎性疾病常引起正中神经受压，对诊断和治疗管理产生了持续的需求。美国风湿病学会于2024年11月发表的一项题为《腕管综合症：类风湿性关节炎早期未被识别的特征》的研究证实，类风湿性关节炎患者的腕管综合征患病率比非患者高1.5倍，凸显了慢性疾病与整形外科神经病变之间的关联。这种关联加剧了疾病的整体负担。 2024年12月，美国国立卫生研究院（NIH）估计，全球腕隧道症候群的盛行率已达总合%，显示治疗市场潜力巨大。

市场挑战

手术减压的高昂费用以及治疗带来的沉重经济负担是全球腕管综合症市场成长的主要障碍。这些经济障碍直接限制了患者获得先进手术介入的机会，尤其是在医疗保险报销有限或自付费用过过高的地区。随着医疗保健总成本的上升，医疗服务提供者和保险公司更有奖励推迟侵入性手术，优先考虑保守的非手术治疗。这降低了对手术器械和设备的即时需求。这种成本敏感性迫使支付方实施更严格的合格标准和更长的等待期，最终导致手术数量减少。

此外，高昂的成本造成了复杂的报销环境，阻碍了市场推广。根据美国国家安全委员会统计，2024年腕隧道症候群的平均劳工赔偿金额约为34,000美元，这反映了该疾病带来的巨大经济负担。这些飙升的成本限制了外科治疗方案生产商的商机，并阻碍了先进治疗方法的广泛应用。

市场趋势

将人工智慧 (AI) 和机器学习应用于诊断领域，显着提升了正中神经病变的辨识率。如今，演算法能够辅助临床医生自动分割超音波影像中的神经边界，最大限度地减少观察者间的差异，并提高诊断的准确性。这项技术突破使得早期发现传统人工评估中常被忽略的细微形态学变化成为可能，从而降低了复杂病例的误诊率。根据 ReachMD 于 2025 年 3 月发表的题为「革新腕管综合症诊断」的报导，近期使用人工智慧增强超音波系统的研究实现了 0.96 的诊断准确率，显着优于传统的影像分析方法，并简化了临床工作流程。

同时，再生医学和生物疗法的日益普及正在改变保守治疗的格局。与仅能暂时缓解症状的皮质类固醇不同，富血小板血浆（PRP）等骨生物製药透过提供生长因子，着重于修復神经组织和恢復生理功能。这种方法不仅能消除炎症，还能修復潜在的神经损伤，为患者提供了一种无需手术减压的持久治疗方案。根据美国神经病学会2025年4月发表的论文《富血小板血浆与类固醇注射疗效比较》，PRP治疗组的症状严重程度评分为-1.31，显着低于皮质类固醇治疗组的-0.79，这支持了生物干预的治疗效果。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球腕隧道症候群市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 依类型诊断（电生理检查、影像检查）
    • 治疗方法（药物治疗、综合治疗、手术）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美腕隧道症候群市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲腕隧道症候群市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区腕隧道症候群市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲腕管综合症市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲腕管综合症市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球腕隧道症候群市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • Stryker Corporation
  • Smith & Nephew Plc
  • CONMED Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27654

The Global Carpal Tunnel Syndrome Market is projected to expand from USD 981.23 Million in 2025 to USD 1216.71 Million by 2031, reflecting a CAGR of 3.65%. This market sector encompasses surgical instruments, pharmaceuticals, and medical devices used to diagnose and manage median nerve compression within the wrist. Key factors driving this growth include the rising prevalence of repetitive strain injuries attributed to increased digitalization and sedentary lifestyles, alongside an aging global population susceptible to musculoskeletal disorders. Additionally, the growing incidence of comorbidities such as obesity and diabetes continues to increase the volume of patients requiring clinical intervention. Data from the Health and Safety Executive indicates that in 2024, 105 new cases of Carpal Tunnel Syndrome were officially assessed under the Industrial Injuries Disablement Benefit scheme in Great Britain, underscoring the persistent occupational nature of the condition.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 981.23 MIllion
Market Size 2031USD 1216.71 MIllion
CAGR 2026-20313.65%
Fastest Growing SegmentMedication
Largest MarketNorth America

Despite these favorable growth drivers, the market encounters significant obstacles due to the high costs of surgical release procedures and the risk of post-operative complications. Financial limitations in developing regions, combined with the availability of alternative non-invasive therapies, often lead patients to delay or avoid advanced medical treatments. These economic constraints and the preference for conservative care options effectively restrain the overall expansion of the market.

Market Driver

The rising adoption of minimally invasive surgical techniques, specifically ultrasound-guided carpal tunnel release, acts as a major catalyst for market growth. These advanced procedures offer smaller incisions and reduced recovery times compared to traditional open surgery, encouraging patient acceptance and facilitating a shift toward cost-effective office-based settings. This technological evolution meets the demand for outpatient care while alleviating the economic burden associated with hospital stays. According to a June 2024 announcement by Sonex Health regarding an ECRI favorable rating, physicians have performed more than 31,000 ultrasound-guided carpal tunnel release procedures, highlighting the rapid clinical integration of this technology. This increase in procedural volume reflects the market's pivot toward device-centric solutions that minimize healthcare resource utilization.

Concurrently, the escalating incidence of associated comorbidities, including metabolic disorders and rheumatoid arthritis, continues to broaden the patient base requiring intervention. Systemic inflammatory conditions frequently trigger median nerve compression, creating sustained demand for diagnostic and therapeutic management. A study published by the American College of Rheumatology in November 2024, titled 'Carpal Tunnel Syndrome Is an Early Unrecognized Feature of Rheumatoid Arthritis,' identified the condition as being 1.5 times more common in individuals with rheumatoid arthritis than in those without, emphasizing the link between chronic disease and orthopedic neuropathy. This correlation amplifies the overall disease burden, with the National Institutes of Health estimating in December 2024 that the combined global prevalence of Carpal Tunnel Syndrome has reached 14.4%, indicating a substantial market for therapeutic providers.

Market Challenge

The substantial expense associated with surgical release procedures and the broader economic burden of treatment constitute a primary impediment to the growth of the Global Carpal Tunnel Syndrome Market. These financial barriers directly limit patient access to advanced surgical interventions, particularly in regions where healthcare reimbursement is restricted or out-of-pocket costs are prohibitive. As the total cost of care increases, healthcare providers and insurers are increasingly incentivized to delay invasive procedures in favor of conservative, non-surgical alternatives, thereby reducing the immediate demand for surgical devices and instrumentation. This sensitivity to cost compels payers to enforce stricter eligibility criteria or prolonged wait times, effectively throttling the volume of surgeries performed.

Furthermore, the high costs create a difficult reimbursement environment that suppresses market adoption rates. According to the National Safety Council, the average workers' compensation settlement for a Carpal Tunnel Syndrome claim was approximately $34,000 in 2024, reflecting the considerable financial liability associated with the condition. Such elevated costs restrict revenue opportunities for manufacturers of surgical solutions and hamper the widespread adoption of advanced treatment modalities.

Market Trends

The integration of Artificial Intelligence and Machine Learning into diagnostics is significantly advancing the identification of median nerve pathology. Algorithms now assist clinicians by automating the segmentation of nerve boundaries in ultrasound imagery, which minimizes inter-observer variability and boosts diagnostic confidence. This technological leap enables earlier detection of subtle morphological changes that traditional manual assessments might miss, reducing misdiagnosis rates in complex cases. According to a ReachMD article from March 2025 titled 'Revolutionizing Carpal Tunnel Syndrome Diagnosis,' recent studies utilizing AI-enhanced ultrasound systems demonstrated a diagnostic accuracy of 0.96, significantly outperforming conventional imaging interpretation methods and streamlining clinical workflows.

Simultaneously, the rising utilization of regenerative medicine and biologic therapies is shifting the landscape of conservative management. Unlike corticosteroids, which offer temporary symptom relief, orthobiologics such as platelet-rich plasma (PRP) focus on repairing neural tissue and restoring physiological function through growth factor delivery. This approach targets the underlying nerve damage rather than merely suppressing inflammation, offering patients a durable alternative to surgical decompression. As reported by the American Academy of Neurology in an April 2025 abstract titled 'Efficacy of Platelet-rich Plasma Versus Steroid Injections,' patients treated with PRP exhibited a superior long-term reduction in symptom severity scores of -1.31 compared to -0.79 for those receiving corticosteroids, highlighting the therapeutic efficacy of biologic interventions.

Key Market Players

  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • Stryker Corporation
  • Smith & Nephew Plc
  • CONMED Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.

Report Scope

In this report, the Global Carpal Tunnel Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carpal Tunnel Syndrome Market, By Diagnosis

  • Electrophysiological Tests
  • Imaging Tests

Carpal Tunnel Syndrome Market, By Treatment

  • Medication
  • Integrative Therapy
  • Surgery

Carpal Tunnel Syndrome Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Carpal Tunnel Syndrome Market.

Available Customizations:

Global Carpal Tunnel Syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Carpal Tunnel Syndrome Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Diagnosis (Electrophysiological Tests, Imaging Tests)
    • 5.2.2. By Treatment (Medication, Integrative Therapy, Surgery)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Carpal Tunnel Syndrome Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Diagnosis
    • 6.2.2. By Treatment
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Carpal Tunnel Syndrome Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Diagnosis
        • 6.3.1.2.2. By Treatment
    • 6.3.2. Canada Carpal Tunnel Syndrome Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Diagnosis
        • 6.3.2.2.2. By Treatment
    • 6.3.3. Mexico Carpal Tunnel Syndrome Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Diagnosis
        • 6.3.3.2.2. By Treatment

7. Europe Carpal Tunnel Syndrome Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Diagnosis
    • 7.2.2. By Treatment
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Carpal Tunnel Syndrome Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Diagnosis
        • 7.3.1.2.2. By Treatment
    • 7.3.2. France Carpal Tunnel Syndrome Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Diagnosis
        • 7.3.2.2.2. By Treatment
    • 7.3.3. United Kingdom Carpal Tunnel Syndrome Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Diagnosis
        • 7.3.3.2.2. By Treatment
    • 7.3.4. Italy Carpal Tunnel Syndrome Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Diagnosis
        • 7.3.4.2.2. By Treatment
    • 7.3.5. Spain Carpal Tunnel Syndrome Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Diagnosis
        • 7.3.5.2.2. By Treatment

8. Asia Pacific Carpal Tunnel Syndrome Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Diagnosis
    • 8.2.2. By Treatment
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Carpal Tunnel Syndrome Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Diagnosis
        • 8.3.1.2.2. By Treatment
    • 8.3.2. India Carpal Tunnel Syndrome Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Diagnosis
        • 8.3.2.2.2. By Treatment
    • 8.3.3. Japan Carpal Tunnel Syndrome Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Diagnosis
        • 8.3.3.2.2. By Treatment
    • 8.3.4. South Korea Carpal Tunnel Syndrome Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Diagnosis
        • 8.3.4.2.2. By Treatment
    • 8.3.5. Australia Carpal Tunnel Syndrome Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Diagnosis
        • 8.3.5.2.2. By Treatment

9. Middle East & Africa Carpal Tunnel Syndrome Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Diagnosis
    • 9.2.2. By Treatment
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Carpal Tunnel Syndrome Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Diagnosis
        • 9.3.1.2.2. By Treatment
    • 9.3.2. UAE Carpal Tunnel Syndrome Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Diagnosis
        • 9.3.2.2.2. By Treatment
    • 9.3.3. South Africa Carpal Tunnel Syndrome Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Diagnosis
        • 9.3.3.2.2. By Treatment

10. South America Carpal Tunnel Syndrome Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Diagnosis
    • 10.2.2. By Treatment
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Carpal Tunnel Syndrome Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Diagnosis
        • 10.3.1.2.2. By Treatment
    • 10.3.2. Colombia Carpal Tunnel Syndrome Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Diagnosis
        • 10.3.2.2.2. By Treatment
    • 10.3.3. Argentina Carpal Tunnel Syndrome Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Diagnosis
        • 10.3.3.2.2. By Treatment

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Carpal Tunnel Syndrome Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GlaxoSmithKline Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Johnson & Johnson
  • 15.4. Novartis AG
  • 15.5. Stryker Corporation
  • 15.6. Smith & Nephew Plc
  • 15.7. CONMED Corporation
  • 15.8. Teva Pharmaceutical Industries Ltd.
  • 15.9. Bristol-Myers Squibb Company
  • 15.10. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer